BANK VONTOBEL/PUT/ABBOTT LABORATORIES/92/0.1/20.09.24 Stock

Warrant

DE000VM3MDE3

Delayed Deutsche Boerse AG 08:06:45 2024-07-11 am EDT
0.093 EUR -1.06% Intraday chart for BANK VONTOBEL/PUT/ABBOTT LABORATORIES/92/0.1/20.09.24
Current month+62.07%
1 month+91.84%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-11 0.093 -1.06%
24-07-10 0.094 -18.26%
24-07-09 0.115 +23.66%
24-07-08 0.093 +22.37%
24-07-05 0.076 -14.61%

Delayed Quote Deutsche Boerse AG

Last update July 11, 2024 at 08:06 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellPUT
Underlying ABBOTT LABORATORIES
IssuerLogo Issuer Vontobel Vontobel
WKN VM3MDE
ISINDE000VM3MDE3
Date issued 2023-10-06
Strike 92 $
Maturity 2024-09-20 (71 Days)
Parity 10 : 1
Emission price 0.62
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.85
Lowest since issue 0.042
Spread 0.01
Spread %10.00%

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Sector
-
More about the company

Ratings for Abbott Laboratories

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Abbott Laboratories

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
103 USD
Average target price
124.8 USD
Spread / Average Target
+21.08%
Consensus